Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals — Investor Presentation (October 2018)
41 slides from Constellation Pharmaceuticals's investor presentation, Oct 11, 2018
Slide 1: Corporate Overview October 2018
Developing Treatments Targeting Epigenetic Mechanisms in Tumor and Immune Cells for Cancer Patients Corporate Overview October 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the anticipated benefits of
Slide 3: Constellation Highlights
Multiple Lead Clinical Programs CPI-1205 (EZH2) and CPI-0610 (BET) Encouraging Preliminary Clinical Data Prostate cancer, solid tumors and myelofibrosis Near-Term Milestones Proof-of-concept determination for each lead program expected in mid-2019 Expanding the EZH2 Opportunity Second-generation EZH
Slide 4: Instructions for Genetic Code
Instructions for Genetic Code Transcriptional control to turn genes on or off Tumor Cells MDSC Tumor microenvironment NK Cell T Cell Target transcriptional networks that result in cell death Re-program immune cells to overcome resistance to cancer immunotherapies Focused on three distinct classes th
Slide 5: Multiple Near-Term Opportunities for Success
Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Next Milestone EZH2 Franchise CPI-1205 mCRPC Proof of Concept Mid 2019 CPI-1205 Solid Tumors Safety and RP2D Early 2019 CPI-0209 (2nd Gen) Solid Tumors / Heme Malignancies BET Inhibitor CP
Slide 6: CPI-1205 and CPI-0209 EZH2 Franchise
CPI-1205 and CPI-0209 EZH2 Franchise
Slide 7: EZH2 Inhibition Offers Broad Therapeutic Potential
EZH2 Inhibition Offers Broad Therapeutic Potential EZH2 “Writer” Activity Suppresses Gene Transcription EZH2 Polycomb Repressive Complex 2 (PRC2)… SUPPRESSED TRANSCRIPTION … methylates Histone H3 at Lysine 27 (K27) Regulation of Immune Cells: EZH2 reprograms T cells to suppress an anti-tumor immune
Slide 8: Expanding EZH2 Opportunity
Expanding EZH2 Opportunity Mutant follicular lymphoma Solid tumors in combination with standard of care in both tumors and immune cells mCRPC Anti-PD-1 Progressors Solid tumors and/or heme malignancies Genetics that validate EZH2 Enhance effectiveness of standard of care Comprehensive target engagem
Slide 9: Model for EZH2 Role in Prostate Cancer
Model for EZH2 Role in Prostate Cancer *Signature of H3K27me3-occupied EZH2 target genes repressed in metastatic relative to clinically localized prostate cancer and benign prostate tissue Yu et al., Cancer Research 2007 EZH2 gene signature* predicts outcomes in prostate cancer Pro-tumor signaling E
Slide 10: Evidence of EZH2 Synergy With Androgen Receptor Signaling
Evidence of EZH2 Synergy With Androgen Receptor Signaling (ARS) CPI-1205 enhances the gene signature of enzalutamide in prostate cancer cells Enzalu- tamide CPI- 1205 Combo CPI-1205 is active as monotherapy and synergistic with enzalutamide in killing prostate cancer cells
Slide 11: Current Treatment Paradigm in mCRPC
Current Treatment Paradigm in mCRPC *ASCO 2018 Poster Khalaf, et al (Kim Chi Lab) Metastatic Castration-Resistant Prostate Cancer (30,000-50,000 Diagnosed Annually) 1st Line Abiraterone or Enzalutamide 2nd Line Enzalutamide or Abiraterone 3rd Line Chemotherapy or Palliative Care 60-80% PSA Response*
Slide 12: ProSTAR Trial Design
ProSTAR Trial Design Second-Line Trial After Ineffective Treatment with Androgen Receptor Signaling (ARS) Inhibitor Randomized Phase 2 Phase 1b Enzalutamide + CPI-1205 (Prior Abiraterone Progression) Abiraterone + CPI-1205 (Prior Enzalutamide Progression) Selected ARS Inhibitor + CPI-1205 (Progresse
Slide 13: ProSTAR Trial: Treatment Duration
ProSTAR Trial: Treatment Duration Data cutoff May 25, 2018 *Continued on CPI-1205 monotherapy after cycle 1 Discontinued Treatment Cycles of treatment (one cycle = one month) Patient # 1 2 3 4 5 6 7 8 9 10 CPI-1205 + Abiraterone CPI-1205 + Enzalutamide C1D1 C2D1 C3D1 C4D1 C5D1 C6D1 C7D1 * 2 of 6 eva
Slide 14: Resolution of Bone Metastases
Resolution of Bone Metastases *Continued on CPI-1205 monotherapy after cycle 1 Baseline Cycle 4 Day 1 CPI-1205 + Enzalutamide*
Slide 15: Objective Response by CT Scan
Objective Response by CT Scan CPI-1205 + Enzalutamide February 2018 Baseline: December 2017
Slide 16: Experience with a Compassionate-Use Patient
Experience with a Compassionate-Use Patient Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient 3,000 2,500 2,000 1,500 1,000 500 12 agents prior to CPI-1205, including second-generation androgen inhibitors, chemotherapy, PARP inhibitors, tyrosine kinase inhibitors, checkpoint in
Slide 17: CPI-1205 Improves Anti-Tumor Immune Activity
CPI-1205 Improves Anti-Tumor Immune Activity Pam Sharma June 2018 Jeff Bluestone and Michel DuPage June 2018 Synergistic impact with checkpoint inhibitor in preclinical model MB49
Slide 18: CPI-1205 Checkpoint Combination Study Design
CPI-1205 Checkpoint Combination Study Design Enrolling All Comers in Solid Tumors Phase 2 Phase 1b Ipilimumab + CPI-1205 (Prior Anti-PD-(L)1) Pembrolizumab + CPI-1205 (Prior Anti-PD-(L)1) RP2D Expansion Cohorts Checkpoint Inhibitor + CPI-1205 Testing Biomarkers for Patient Enrichment
Slide 19: Clinical Activity Observed in Anti-PD-1 Progressors
Clinical Activity Observed in Anti-PD-1 Progressors ORIOn-E Summary as of May 25, 2018 Discontinued Treatment Stable Disease Partial Response Treatment Ongoing CPI-1205 +pembrolizumab CPI-1205 + ipilimumab 1 2 3 4 5 6 7 8 9 Baseline Cycle 4 42% Reduction in Tumor Volume from Baseline Phase 1b/2 All
Slide 20: CPI-0209: Second-Generation EZH2 Inhibitor
CPI-0209: Second-Generation EZH2 Inhibitor Once-Daily Treatment Resulted in Rapid, Complete, and Durable Tumor Regression Vehicle Tazemetostat, 160 mg/kg oral, twice daily Lymphoma Xenograft Mouse Model Expected to enter Phase 1 in 2019 CPI-0209 may provide more comprehensive EZH2 coverage, expandin
Slide 21: CPI-0610 BET Inhibitor
CPI-0610 BET Inhibitor
Slide 22: BET Reader Proteins and Opportunity in Myelofibrosis
BET “Reader” Proteins Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) Enhancer TSS BRD4 Transcription Factor … … Fibrosis TGF-β target genes Immune Signaling NF-κB target genes Cancer Genetics MYC, BCL2
Slide 23: Mechanism of Action
Mechanism of Action BET Inhibition May Block Proliferation of Inflammatory Bone Marrow Cells and Synergize with JAK Inhibition BET Signaling Megakaryocyte Differentiation/Proliferation Pro-inflammatory Cytokines (e.g. IL-8) JAK/STAT Signaling STAT STAT Cytoplasm Nucleus NF-kB Target Genes BETs P P
Slide 24: Rationale for BET's Role in Myelofibrosis
Rationale for BET’s Role in Myelofibrosis CPI-0610 vs DMSO 25 nM 100 nM 400 nM Inhibition of Megakaryocyte Differentiation in vitro BET inhibitor + ruxolitinib led to synergistic reduction in spleen volume (left) and improved bone marrow fibrosis score (right) Kleppe et al 2018 Cancer Cell Vehicle 1
Slide 25: Myelofibrosis (MF) Background
Myeloproliferative neoplasm characterized by scarring (fibrosis) of the bone marrow caused by impaired hematopoiesis 17,000-20,000 patients in US* Three main features: Symptoms of organomegaly (spleen and liver) Symptoms of systemic inflammation Anemia and thrombocytopenia Only approved therapy is r
Slide 26: Underserved MF Patient Population
Standard of care and the only approved drug treatment is ruxolitinib (Jakafi) Significant improvement in splenomegaly and symptoms, but limited evidence of disease modifying effect 30-40% of patients respond adequately in clinical trials* Thrombocytopenia and/or anemia may lead to patients receiving
Slide 27: Need for New Disease-Modifying Treatments in MF
Need for New Disease-Modifying Treatments in MF Ruxolitinib Spleen Response – SIMPLIFY-1* Ruxolitinib TSS Response – SIMPLIFY-1* Inadequate response in 1L disease No approved therapy in 2L disease Patients burdened by increased reliance on transfusions Need for new disease-modifying therapies that i
Slide 28: CPI-0610 Background
Treated 138 patients in Phase 1 trials of hematologic malignancies Multiple objective responses observed at a range of doses below the maximum tolerated dose Demonstrated favorable PK/PD profile Activity seen in the context of NF-κB-driven diseases ABC-DLBCL (Phase 1) 7 patients at relevant doses: 1
Slide 29: MANIFEST: CPI-0610 Phase Trial Design in MF
MANIFEST: CPI-0610 Phase 2 Trial Design in MF Prior to Amendment CPI-0610 n=35 CPI-0610 dosing of 125mg up to 225mg once daily in both arms 2L MF patients no longer on ruxolitinib 2L MF patients on ruxolitinib despite disease progression on therapy CPI-0610 + ruxolitinib n=35 Objectives: Evaluate sp
Slide 30: Spleen Size Reduced in All Patients as Measured by MRI
Spleen Size Reduced in All Patients as Measured by MRI MANIFEST: First Four Patients Treated Ongoing > 10 months Ongoing > 5 months Reduced spleen size Symptom improvement One patient with thrombocytosis and one patient transfusion-dependent at baseline—both resolved Data cutoff May 25, 2018
Slide 31: Improved Hematopoiesis on CPI-0610
Improved Hematopoiesis on CPI-0610 Patient Achieved Transfusion Independence and Improved Platelet Count Patient treated with CPI-0610 + ruxolitinib combination therapy Data cutoff May 25, 2018
Slide 32: Improved Hematopoiesis on CPI-0610
Improved Hematopoiesis on CPI-0610 Hemoglobin Levels Increased in First Four Patients Treated Data cutoff May 25, 2018
Slide 33: Clinical Trial Execution
All patient data disclosed to date come from our first site We have made considerable progress in our 2018 goals of activating additional sites 7 sites in the US and 5 in Canada are active, with more to follow in US and Europe We have enrolled additional patients at these sites and look forward to p
Slide 34: Rationale for Protocol Amendment
Preliminary signs of clinical activity in each of the evaluable 2L patients in MANIFEST* SVR and symptom improvement Potential disease-modifying effects* Improved hematopoiesis, including hemoglobin level improvement, in each patient Resolution of transfusion dependence Modifying the 2L cohorts to s
Slide 35: MANIFEST: Expanded Phase Trial in MF
MANIFEST: Expanded Phase 2 Trial in MF *Cohort 3 will enroll anemic patients, pivotal trial plans anticipated to include all comers Robust Development Plan to Expand the CPI-0610 Opportunity 2L MF patients no longer on ruxolitinib 2L MF patients on ruxolitinib despite disease progression on therapy
Slide 36: CPI-0610 Summary
CPI-0610 has demonstrated clinical activity in early clinical trials with NF-κB-driven cancers, including MF, suggesting CPI-0610 may be differentiated among BET inhibitors Early clinical data in 2L myelofibrosis show improvements in spleen volume, symptom scores, hematopoiesis, and transfusion inde
Slide 37: Discovery Platform Fueling the Pipeline
Discovery Platform Fueling the Pipeline Tumor Cells Innate Adaptive Discovery Programs Targeting Epigenetic Regulators on the Tumor and Immune Microenvironment Normalize aberrant gene expression within cancer cells Increase tumor immunogenicity Re-program immune cells to overcome resistance to cance
Slide 38: Financial Strength
Financial Strength
Slide 39: Potential Value Creation Catalysts
Potential Value Creation Catalysts Early 2018 Complete crossover financing Expand enrollment in ProSTAR Initiate ORIOn-E Select 2nd generation EZH2 inhibitor candidate (CPI-0209) Late 2018 Additional active sites in US, Canada / EU for CPI-0610 in myelofibrosis Initiate Phase 2 portion of ProSTAR Tr
Slide 40: Strong Cash Position
Post-IPO cash expected to fund operations into 2020, including: Ongoing clinical trials to determine proof of concept for CPI-1205 and CPI-0610 Continued advancement of CPI-0209 Ongoing support for robust discovery/preclinical Oversubscribed crossover financing round in April raised $100 million fro
Slide 41: Experienced Management Team, Board, and Scientific Advisors
Experienced Management Team, Board, and Scientific Advisors Jigar Raythatha President and CEO Emma Reeve Chief Financial Officer Adrian Senderowicz, M.D. Chief Medical Officer Brad Prosek SVP, Corporate Development Robert Sims, PhD SVP, Research Patrick Trojer, PhD SVP, Translational Sciences Manage
Constellation Pharmaceuticals — Investor Presentation (October 2018) on 6ix